Thu. 29 Feb 2024, 8:12am ET
Benzinga
Earnings, News
VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.50) by 64 percent. This is a 93.94 percent increase over losses of $(2.97) per share from the same period last year. The company reported quarterly sales of $76.00 thousand which missed the analyst consensus estimate of $150.00 thousand by 49.33 percent. This is a 1.17K percent increase over sales of $6.00 thousand the same period last year.